Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-04-14 | Dr. Jeffrey Alan GravesPresident, CEO & Director | -30,50k | 60,39k | Sale to Issuer | 1,98 | 1,43M | -2,09% |
| 2026-04-14 | Ms. Phyllis B. NordstromExec. VP, CFO & Chief Administrative Officer | -1,63k | 3,22k | Sale to Issuer | 1,98 | 793,27k | -0,20% |
| 2026-04-14 | Mr. Reji PuthenveetilExec. VP of Additive Solutions & Chief Commercial Officer | -11,70k | 23,17k | Sale to Issuer | 1,98 | 502,13k | -2,28% |
| 2026-04-14 | Dr. Joseph ZuikerExec. VP of Engineering & Operations | -5,33k | 10,55k | Sale to Issuer | 1,98 | 278,05k | -1,88% |
| 2026-04-14 | Dr. Charles W. HullCo-Founder, Exec. VP, CTO of Regenerative Medicine & Director Emeritus | -4,10k | 8,12k | Sale to Issuer | 1,98 | 518,52k | -0,78% |
| 2026-04-01 | Dr. Charles W. HullCo-Founder, Exec. VP, CTO of Regenerative Medicine & Director Emeritus | -4,46k | 8,34k | Sale to Issuer | 1,87 | 522,62k | -0,85% |
| 2026-04-01 | Mr. Reji PuthenveetilExec. VP of Additive Solutions & Chief Commercial Officer | -17,70k | 33,10k | Sale to Issuer | 1,87 | 513,83k | -3,33% |
| 2026-04-01 | Dr. Joseph ZuikerExec. VP of Engineering & Operations | -8,32k | 15,56k | Sale to Issuer | 1,87 | 283,38k | -2,85% |
| 2026-04-01 | Ms. Phyllis B. NordstromExec. VP, CFO & Chief Administrative Officer | -14,52k | 27,15k | Sale to Issuer | 1,87 | 794,89k | -1,79% |
| 2026-04-01 | Dr. Jeffrey Alan GravesPresident, CEO & Director | -39,95k | 74,71k | Sale to Issuer | 1,87 | 1,46M | -2,66% |
| 2026-04-01 | Mr. Andrew William-Banasick WrightSenior VP of General Counsel & Corporate Secretary | -3,86k | 7,22k | Sale to Issuer | 1,87 | 142,78k | -2,63% |
| 2025-12-12 | Dr. Joseph ZuikerExec. VP of Engineering & Operations | -5,21k | 9,90k | Sale to Issuer | 1,90 | 199,20k | -2,55% |
| 2025-12-02 | Ms. Phyllis B. NordstromExec. VP, CFO & Chief Administrative Officer | -1,73k | 3,53k | Sale to Issuer | 2,04 | 634,41k | -0,27% |
| 2025-09-05 | Dr. Charles W. HullCo-Founder, Exec. VP, CTO of Regenerative Medicine & Director Emeritus | -4,93k | 10,45k | Sale to Issuer | 2,12 | 477,08k | -1,02% |
| 2025-09-05 | Mr. Andrew William-Banasick WrightSenior VP of General Counsel & Corporate Secretary | -5,86k | 12,41k | Sale to Issuer | 2,12 | - | - |
| 2025-09-05 | Dr. Joseph ZuikerExec. VP of Engineering & Operations | -6,73k | 14,27k | Sale to Issuer | 2,12 | 204,41k | -3,19% |
| 2025-09-05 | Ms. Phyllis B. NordstromExec. VP, CFO & Chief Administrative Officer | -13,39k | 28,38k | Sale to Issuer | 2,12 | 636,14k | -2,06% |
| 2025-09-05 | Mr. Reji PuthenveetilExec. VP of Additive Solutions & Chief Commercial Officer | -16,05k | 34,03k | Sale to Issuer | 2,12 | 431,53k | -3,59% |
| 2025-09-05 | Dr. Jeffrey Alan GravesPresident, CEO & Director | -40,13k | 85,07k | Sale to Issuer | 2,12 | 1,25M | -3,11% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
